IDYA
IDEAYA Biosciences, Inc.Company with tickers: IDYA
Market Cap
$3.23B
Shares Outstanding
87,860,920
CIK
1676725
CUSIP
45166A102
13F Activity (30d)
1 filings
1 filers
Website
Visit website
Investor Relations
Investor relations
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $6,560,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Interest & Dividend Income | — | ||||
| Net Interest Income | — | ||||
| Noninterest Income | — | ||||
| Total Net Revenue | — | ||||
| Premiums Earned (Net) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $115,104,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Research & Development | $95,726,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Operating Income | $-108,544,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Net Income | $-98,539,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Basic) | $-1.11 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Diluted) | $-1.11 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |